Swee Heng Milon Pang

Swee Heng Milon Pang

Auto-generated profile, based on publicly available information

Swee Heng Milon Pang

Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Immunity
Verified
Journal Article
Closed access
SCSebastian Carotta
Sebastian Carotta
ADAleksandar Dakic
Aleksandar Dakic
ADAngela D'AMico
Angela D'AMico
SPSwee Heng Milon Pang
Swee Heng Milon Pang
KGKylie T. Greig
Kylie T. Greig
LWLi Wu
Li Wu

11 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSwee Heng Milon Pang
Swee Heng Milon Pang
JDJoshua D’rozario
Joshua D’rozario
SMSenora Mendonca
Senora Mendonca
TBTejasvini Bhuvan
Tejasvini Bhuvan
NPNatalie L. Payne
Natalie L. Payne
THTracy Heng
Tracy Heng
Multipotent mesenchymal stromal cells (MSCs) ameliorate a wide range of diseases in preclinical models, but the lack of clarity around their mechanisms of action has impeded their clinical utility. The therapeutic effects of MSCs are often attributed to bioactive molecules secreted by viable MSCs. However, we found that MSCs underwent apoptosis in the lung after intravenous administration, even in the absence of host cytotoxic or alloreactive cells. Deletion of the apoptotic effectors BAK and BAX prevented MSC death and attenuated their immunosuppressive effects in disease models used to define MSC potency. Mechanistically, apoptosis of MSCs and their efferocytosis induced changes in metabolic and inflammatory pathways in alveolar macrophages to effect immunosuppression and reduce disease severity. Our data reveal a mode of action whereby the host response to dying MSCs is key to their therapeutic effects; findings that have broad implications for the effective translation of cell-based therapies.

19 May 2011 in Blood
Verified
Journal Article
Open access
PDF file
SCSebastian Carotta
Sebastian Carotta
SPSwee Heng Milon Pang
Swee Heng Milon Pang
SNStephen Nutt
Stephen Nutt
GBGabrielle T. Belz
Gabrielle T. Belz
Natural killer (NK) cells are generated in the bone marrow (BM) from lymphoid progenitors. Although several different maturation states of committed NK cells have been described, the initial stages of NK-cell differentiation from the common lymphoid progenitor are not well understood. Here we describe the identification of the earliest committed NK-cell precursors in the BM. These precursors, termed pre-pro NK cells, lack the expression of most canonical NK cell–specific surface markers but express the transcription factor inhibitor of DNA binding 2 and high levels of the IL-7 receptor. In vitro differentiation studies demonstrate that pre-pro NK cells are committed to NK-cell lineage and appear to be upstream of the previously identified NK-cell progenitor population.

6 October 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SCSebastian Carotta
Sebastian Carotta
SWSimon N. Willis
Simon N. Willis
JHJhagvaral Hasbold
Jhagvaral Hasbold
MIMichael Inouye
Michael Inouye
SPSwee Heng Milon Pang
Swee Heng Milon Pang
SNStephen Nutt
Stephen Nutt
Activated B cells undergo immunoglobulin class-switch recombination (CSR) and differentiate into antibody-secreting plasma cells. The distinct transcriptomes of B cells and plasma cells are maintained by the antagonistic influences of two groups of transcription factors: those that maintain the B cell program, including BCL6 and PAX5, and plasma cell–promoting factors, such as IRF4 and BLIMP-1. We show that the complex of IRF8 and PU.1 controls the propensity of B cells to undergo CSR and plasma cell differentiation by concurrently promoting the expression of BCL6 and PAX5 and repressing AID and BLIMP-1. As the PU.1–IRF8 complex functions in a reciprocal manner to IRF4, we propose that concentration-dependent competition between these factors controls B cell terminal differentiation.

8 April 2010 in Blood
Verified
Journal Article
Closed access
PDF file
KGKylie T. Greig
Kylie T. Greig
CGCarolyn A. de Graaf
Carolyn A. de Graaf
JMJames M. Murphy
James M. Murphy
MCMarina R. Carpinelli
Marina R. Carpinelli
SPSwee Heng Milon Pang
Swee Heng Milon Pang
SNStephen Nutt
Stephen Nutt
C-Myb is a transcription factor with functions in many hematopoietic lineages. c-Myb–deficient mice display reduced numbers of B cells; however, it is unknown what role c-Myb plays in B lymphopoiesis because no critical target genes have been identified in the B-cell lineage. We demonstrate that conditional deletion of c-Myb in B-cell progenitors completely abolishes B-cell development. c-Myb is required for lymphoid progenitors to respond to the cytokines interleukin-7 and thymic stromal lymphopoietin; in the absence of sufficient c-Myb activity, mice display a B lymphopenia that closely resembles that observed in interleukin-7 receptor α–deficient animals. Analysis of the multipotent progenitor compartment indicates that c-Myb is also required for up-regulation of multiple lymphoid-associated genes, including Il7r, and for the subsequent development of the common lymphoid progenitor population. These data show that c-Myb plays a critical role in the regulatory pathways governing lymphoid specification and early B-cell differentiation.

2 March 2016 in Leukemia
Verified
Journal Article
Closed access
PDF file
SPS H M Pang
S H M Pang
MMM Minnich
M Minnich
PGP Gangatirkar
P Gangatirkar
ZZZhiqiang Zheng
Zhiqiang Zheng
AEA Ebert
A Ebert
SCS Carotta
S Carotta